New Drug Review: Tukysa

Inbox

x

MPR First Look <editor@email.empr.com> Unsubscribe

Wed, May 6, 7:05 PM (2 days ago)

to me

If you are having trouble viewing this email, click here.

NEW DRUG PRODUCT: TUKYSA FEATURED Find out more about Tukysa including dosing and important safety information with our slideshow, complete drug monograph, and downloadable PDF. DRUGS IN THE PIPELINE Dapagliflozin To Be Evaluated in COVID-19 Patients With Cardiovascular, Metabolic, or Renal Risk Factors Ultomiris to Be Evaluated for Severe COVID-19 in Phase 3 Trial Daridorexant Improves Sleep, Daytime Performance in Insomnia Study FDA to Review Data on Shorter Infusion Time for MS Drug Ocrevus Solution Stable Glucagon Granted Orphan Drug Status for Congenital Hyperinsulinism The right dose of information. eMPR.com CME/CE Spotlight Dispelling the Myths of Influenza Management AMA PRA Category 1 Credit(s)TM, CNE Contact Hour(s), CE for Pharmacists CLICK HERE FOR A FULL LIST OF COURSES CE/CME Powered By myCME